Form 4: Dianthus Therapeutics CFO & CBO Ryan Savitz Granted Stock Options
SEC Form 4 Filing
Ryan Savitz, CFO & CBO of Dianthus Therapeutics, Inc., was granted stock options to purchase 100,000 shares of common stock on May 23, 2024.
Summary
- On May 23, 2024, Ryan Savitz, the CFO & CBO of Dianthus Therapeutics, Inc., was granted stock options.
- These options allow him to purchase 100,000 shares of Dianthus Therapeutics' common stock at an exercise price of $21.77 per share.
- The stock options vest in equal monthly installments over four years, starting May 1, 2024, contingent upon Savitz's continued service to the company.
- The options expire on May 22, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns executive interests with shareholder value.
Positives
- The granting of stock options to a key executive like the CFO & CBO can be seen as a positive incentive for them to remain with the company and contribute to its success.
- The vesting schedule aligns the executive's interests with the long-term performance of the company.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Granting stock options is a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. This aligns with standard compensation practices in the sector.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Regeneron also use stock options to incentivize their executives.
- The vesting schedule of four years is also a common practice to ensure long-term commitment.
Stakeholder Impact
- Shareholders may view the granting of stock options as a positive incentive for management.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| May 1, 2024 | Start date for the monthly vesting of the stock options. |
| May 23, 2024 | Date of the transaction (grant of stock options). |
| May 22, 2034 | Expiration date of the stock options. |
| May 28, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.